Additionally in 2019, a novel small-molecule inhibitor of apoptosis (via Bcl-2 inhibition) [110], Venetoclax (Venclexta, Venclycto), was approved by the FDA (EMA, in 2020) for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML) [111]. The gene discussed is BCL2; the disease is acute myeloid leukemia.